Repligen
RGEN
#2620
Rank
NZ$11.48 B
Marketcap
NZ$203.73
Share price
-0.31%
Change (1 day)
-5.45%
Change (1 year)
Categories

P/S ratio for Repligen (RGEN)

P/S ratio as of April 2026 (TTM): 9.15

According to Repligen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.21. At the end of 2025 the company had a P/S ratio of 12.5.

P/S ratio history for Repligen from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
202512.5-2.5%
202412.9-20.43%
202316.237.72%
202211.7-46.29%
202121.8-23.72%
202028.660.6%
201917.849.33%
201811.96.67%
201711.212.2%
20169.97-10.61%
201511.29.27%
201410.259.86%
20136.39103.04%
20123.15-8.06%
20113.42-37.77%
20105.50-10%
20096.1145.49%
20084.20-59.34%
200710.360.41%
20066.44-30.4%
20059.25-9.44%
200410.2-46.53%
200319.166.56%
200211.5-35.84%
200117.9

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.47-72.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
4.17-54.38%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
7.20-21.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.52-72.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
3.30-63.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
1.36-85.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
4.62-49.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
7.15-21.84%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
3.36-63.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
2.16-76.43%๐Ÿ‡บ๐Ÿ‡ธ USA